24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gamida Cell
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:38
Who will cover the damages of the largest computer failure in history?
16:00
Scopio Labs secures $42 million Series D for AI-based blood cell analysis
14:47
"Growing high-tech is essential for the economy of the North"
14:31
Full list of Israeli high-tech funding rounds in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
2
JPMorgan CEO Jamie Dimon makes whirlwind visit to Israel
3
From IPO dreams to CrowdStrike’s crisis: Inside the collapse of the Wiz-Google mega deal
4
Amdocs set to cut 1,500-3,000 jobs in new round of layoffs
5
Israel’s Quantum Transistors receives €17.5M from the European Innovation Council for its quantum computing solution
More news
Gamida Cell
5 stories about Gamida Cell
Gamida Cell announces $75 million financing with Highbridge Capital Management
16.02.21
|
CTech
The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases
Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO
28.10.18
|
Lilach Baumer
The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share
Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million
18.10.18
|
Lilach Baumer
The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms
Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO
30.09.18
|
Dror Reich
The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
Please ensure Javascript is enabled for purposes of
website accessibility